Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Letermovir

FDA-approved product (tablet, oral), marketed as Prevymis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Letermovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cytomegalovirus infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
Cytomegalovirus DNA Terminase Complex Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX18

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Letermovir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Letermovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

    NCT06575374 · start 2024-12-12

    Registered record
    Registry ID
    NCT06575374
    Conditions
    Cell Therapy
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-12
    Completion
    2028-08-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCell Therapy
    InterventionLetermovir
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

    NCT06626555 · start 2024-10

    Registered record
    Registry ID
    NCT06626555
    Conditions
    HIV
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionLetermovir
    PhasePhase 2
    Registry statusNot yet recruiting

  • Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

    NCT06407232 · start 2024-08-08

    Registered record
    Registry ID
    NCT06407232
    Conditions
    Cytomegalovirus Infections; Kidney Transplant Infection; Pancreas Transplant
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-08
    Completion
    2027-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Kidney Transplant Infection; Pancreas Transplant
    InterventionLetermovir
    PhasePhase 3
    Registry statusRecruiting

  • A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

    NCT05711667 · start 2024-07-11

    Registered record
    Registry ID
    NCT05711667
    Conditions
    Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions
    Biospecimen Collection; Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-11
    Completion
    2029-06-30
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    InterventionBiospecimen Collection; Letermovir
    PhasePhase 3
    Registry statusRecruiting

  • CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

    NCT06449586 · start 2024-07-01

    Registered record
    Registry ID
    NCT06449586
    Conditions
    Hematologic Malignancy
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-07-01
    Completion
    2026-06-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy
    InterventionLetermovir
    PhasePhase 3
    Registry statusActive not recruiting

  • CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

    NCT06453460 · start 2024-06-27

    Registered record
    Registry ID
    NCT06453460
    Conditions
    CMV; Allogeneic Stem Cell Transplantation
    Interventions
    Letermovir; CMV T Cell Immunity Panel (CMV-TCIP); CMV DNA PCR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-27
    Completion
    2029-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV; Allogeneic Stem Cell Transplantation
    InterventionLetermovir; CMV T Cell Immunity Panel (CMV-TCIP); CMV DNA PCR
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

    NCT06341686 · start 2024-05-05

    Registered record
    Registry ID
    NCT06341686
    Conditions
    CMV Infection
    Interventions
    Letermovir 480 MG; Ganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-05-05
    Completion
    2025-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Infection
    InterventionLetermovir 480 MG; Ganciclovir
    PhasePhase 3
    Registry statusUnknown

  • Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

    NCT06441669 · start 2024-05-01

    Registered record
    Registry ID
    NCT06441669
    Conditions
    Cytomegalovirus Infection Reactivation
    Interventions
    Letermovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-05-01
    Completion
    2026-05-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection Reactivation
    InterventionLetermovir
    PhaseNot recorded
    Registry statusUnknown

  • Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

    NCT06066957 · start 2024-04-04

    Registered record
    Registry ID
    NCT06066957
    Conditions
    Cytomegalovirus Infections; Transplant-Related Disorder
    Interventions
    Letermovir 480 MG [Prevymis]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-04
    Completion
    2026-08-15
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Transplant-Related Disorder
    InterventionLetermovir 480 MG [Prevymis]
    PhasePhase 2
    Registry statusRecruiting

  • Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

    NCT06211543 · start 2024-03-30

    Registered record
    Registry ID
    NCT06211543
    Conditions
    CMV
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-03-30
    Completion
    2026-03-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

    NCT06057194 · start 2023-10

    Registered record
    Registry ID
    NCT06057194
    Conditions
    Infections, Cytomegalovirus
    Interventions
    Letermovir 240 mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-10
    Completion
    2027-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Cytomegalovirus
    InterventionLetermovir 240 mg Oral Tablet
    PhasePhase 2
    Registry statusNot yet recruiting

  • Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

    NCT05914675 · start 2023-07-01

    Registered record
    Registry ID
    NCT05914675
    Conditions
    The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-07-01
    Completion
    2024-12-31
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
    InterventionLetermovir
    PhasePhase 4
    Registry statusUnknown

  • Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

    NCT05914701 · start 2023-07-01

    Registered record
    Registry ID
    NCT05914701
    Conditions
    To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
    Interventions
    Letermovir for secondary prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-07-01
    Completion
    2024-12-31
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTo Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
    InterventionLetermovir for secondary prophylaxis
    PhasePhase 4
    Registry statusUnknown

  • Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

    NCT05432778 · start 2023-05-01

    Registered record
    Registry ID
    NCT05432778
    Conditions
    CMV Viremia
    Interventions
    Letermovir Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2026-08-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Viremia
    InterventionLetermovir Pill
    PhasePhase 2
    Registry statusUnknown

  • Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China

    NCT05789615 · start 2023-04-01

    Registered record
    Registry ID
    NCT05789615
    Conditions
    CMV Infection; Hematopoietic Stem Cell Transplantation
    Interventions
    Letermovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-01
    Completion
    2025-01-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Infection; Hematopoietic Stem Cell Transplantation
    InterventionLetermovir
    PhaseNot recorded
    Registry statusCompleted